USFDA approves Zydus Lifesciences to market generic Micafungin injection
The United States Food and Drug Administration (USFDA) has given its approval to market Micafungin for Injection, 50 mg/vial and 100 mg/vial, single-dose vials, Zydus Lifesciences Ltd said in an exchange filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 26, 2022 Category: Pharmaceuticals Source Type: news

Biotech regulator recommends environmental release of GM mustard
The move comes amid opposition from green groups which say commercial cultivation of GM mustard could have an adverse impact on human health and food security. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 26, 2022 Category: Pharmaceuticals Source Type: news

Piramal Pharma to inject funds into expansion, acquisitions
Piramal Pharma received a $360 million investment from US private equity company Carlyle Group in October 2020 in exchange for a 20% share. Piramal Pharma includes the contract development and manufacturing organisation, called the Piramal Pharma Solutions (PPS), which contributes three-fifths to the revenue. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 25, 2022 Category: Pharmaceuticals Source Type: news

Dr Reddy's, Cipla, Aurobindo units recall products in US market
As per the enforcement report by the US Food and Drug Administration (USFDA), the US-based unit of Dr Reddy's Laboratories is recalling 2,838 ampules of vitamin K deficiency treatment drug Phytonadione Injectable Emulsion. According to the USFDA, Dr Reddy's Laboratories is recalling the affected lot due to "failed stability specifications". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 23, 2022 Category: Pharmaceuticals Source Type: news

HPV vaccine production delayed due to COVID focus, will start supply to Indian govt in early 2023: SII
Exports will have to wait till 2024, its chief executive Adar Poonawalla told reporters here on Thursday evening, adding that the company has to build a scale of manufacturing to over 150 million for that. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 21, 2022 Category: Pharmaceuticals Source Type: news

People fed up with Covid, no takers for boosters, SII not making Covishield since December 2021: Adar Poonawalla
According to the Serum CEO, booster vaccines have no demand because of the "general lethargy among people and also because they are fed up with the pandemic." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news

Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mn
The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news

Glenmark Pharma launches drug for diabetic patients with comorbidities
The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients, he added. Glenmark said Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg per day. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news

You may not get a booster shot at most private facilities
Most private hospital executives ET spoke with said they had stopped procuring Covid vaccines due to tepid demand. The Max Healthcare hospital chain last procured Covishield vaccine five months ago, a spokesperson said. "We have consumed all the stocks," the spokesperson said. "Nowadays rarely people come for the vaccines." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news

Rx Propellant plans Rs 1,100-crore lab in Hyderabad
At Genome Valley, the company plans to develop a 9,00,000 square feet lab space, to be operational over mid-2025. The new cluster will cater to startups, scale-ups and established contract manufacturers and multinationals in the pharma space. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 19, 2022 Category: Pharmaceuticals Source Type: news

Syngene reports Rs 102 crore net profit in Q2FY23
The company reported net profit of Rs 102 crore during Q2FY23, compared to Rs 67 crore during the corresponding quarter of the previous year. Revenues rose 26% YoY to Rs 784 crore in Q2FY23 compared to Rs 623 in the year ago period. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 19, 2022 Category: Pharmaceuticals Source Type: news

US drug maker Baxter opens R & D centre in Ahmedabad
Baxter said the Ahmedabad R&D centre will help the company to accelerate innovation in generic and differentiated injectable pharmaceuticals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2022 Category: Pharmaceuticals Source Type: news

Cipla bets on digitisation to raise the bar on productivity
The firm's spending on digital has touched about ₹100 crore in recent years, said Umang Vohra, managing director and global CEO of Cipla. "In our digital journey, on a zero to 10 scale, we are probably at three or four. We have so much to do," he told ET. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2022 Category: Pharmaceuticals Source Type: news

Johnson & Johnson sells its largest India plant as demand weakens
J&J's manufacturing plant spread across 55.27 acres was completed in 2016 to make consumer health products, including babycare range, beauty, earbuds, electrolyte drinks, oral and skincare. The plant, however, has been idle ever since. The company had to take an impairment charge of about ₹310 crore and put up the plant for sale. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2022 Category: Pharmaceuticals Source Type: news

Zydus Lifesciences gets USFDA nod for 2 generic drugs
The tentative approval granted by the US Food and Drug Administration (USFDA) to the company's arm Zydus Worldwide DMCC to market Valbenazine capsules is for strengths 40 mg, 60 mg, and 80 mg, Zydus Lifesciences said in a regulatory filing. As per IQVIA MAT August 2022 data, Valbenazine capsules had annual sales of USD 781 million in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 17, 2022 Category: Pharmaceuticals Source Type: news